02 September 2024
The drug NIOH-14, developed by employees of the Vorozhtsov Novosibirsk Institute of Organic Chemistry and the State Scientific Center of Virology and Biotechnology “Vector” , has proven effective in preventing infection with monkeypox (mpox). This is the first chemical drug in Russia for the treatment and emergency prevention of smallpox and other orthopoxvirus diseases in humans.
The vaccine affects orthopoxviruses, prevents the appearance of viral particles outside infected cells and thereby suppresses the development of a viral infection. “[Additional] studies were conducted. The drug showed good results. The studies were conducted by the State Research Center Vector,” said Elena Bagryanskaya, director of the Novosibirsk institute.
PrintMerry Christmas and Happy New Year!
28 December 2024
NovaMedica team in the TOP 100 INFLUENTIAL PEOPLE IN THE PHARMACEUTICAL BUSINESS 2024
28 November 2024
05 November 2024
Long-term potential revealed for novel modifier gene therapy
21 January 2025
Binnopharm Group opened an office in Vietnam
21 January 2025
New guidance to aid cost-effectiveness analysis of new drugs
20 January 2025
The Ministry of Health may expand its patent use powers
20 January 2025